BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22381898)

  • 1. Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy.
    Nakamura A; Shibuya K; Matsuo Y; Nakamura M; Shiinoki T; Mizowaki T; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):369-75. PubMed ID: 22381898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.
    Huang J; Robertson JM; Ye H; Margolis J; Nadeau L; Yan D
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1120-5. PubMed ID: 22099048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
    Holyoake DLP; Warren DR; Hurt C; Aznar M; Partridge M; Mukherjee S; Hawkins MA
    Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):418-426. PubMed ID: 29602584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer.
    Kelly P; Das P; Pinnix CC; Beddar S; Briere T; Pham M; Krishnan S; Delclos ME; Crane CH
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e143-9. PubMed ID: 23200173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
    Rakhra S; Strauss JB; Robertson J; McGinn CJ; Kim T; Huang J; Blake A; Helenowski I; Hayes JP; Mulcahy M; Small W
    J Gastrointest Cancer; 2016 Jun; 47(2):196-201. PubMed ID: 27112332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations.
    Huguet F; Goodman KA; Azria D; Racadot S; Abrams RA
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1355-64. PubMed ID: 22768988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer.
    Ito Y; Okusaka T; Kagami Y; Ueno H; Ikeda M; Sumi M; Imai A; Fujimoto N; Ikeda H
    Anticancer Res; 2006; 26(5B):3755-9. PubMed ID: 17094397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer.
    Takatori K; Terashima K; Yoshida R; Horai A; Satake S; Ose T; Kitajima N; Kinoshita Y; Demizu Y; Fuwa N
    J Gastroenterol; 2014 Jun; 49(6):1074-80. PubMed ID: 23846547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer.
    Prasad S; Cambridge L; Huguet F; Chou JF; Zhang Z; Wu AJ; O'Reilly EM; Allen PJ; Goodman KA
    Pract Radiat Oncol; 2016; 6(2):78-85. PubMed ID: 26577010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.
    Simpson DR; Song WY; Moiseenko V; Rose BS; Yashar CM; Mundt AJ; Mell LK
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e81-6. PubMed ID: 22516388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head.
    Raturi VP; Hojo H; Hotta K; Baba H; Takahashi R; Rachi T; Nakamura N; Zenda S; Motegi A; Tachibana H; Ariji T; Motegi K; Nakamura M; Okumura M; Hirano Y; Akimoto T
    Radiat Oncol; 2020 Jun; 15(1):157. PubMed ID: 32571379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
    Olsen JR; Moughan J; Myerson R; Abitbol A; Doncals DE; Johnson D; Schefter TE; Chen Y; Fisher B; Michalski J; Narayan S; Chang A; Crane CH; Kachnic L
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):400-408. PubMed ID: 28463160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.
    Chang JS; Wang ML; Koom WS; Yoon HI; Chung Y; Song SY; Seong J
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1448-54. PubMed ID: 22285669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
    Passoni P; Reni M; Cattaneo GM; Slim N; Cereda S; Balzano G; Castoldi R; Longobardi B; Bettinardi V; Gianolli L; Gusmini S; Staudacher C; Calandrino R; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1000-6. PubMed ID: 24267968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
    Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes.
    Poorvu PD; Sadow CA; Townamchai K; Damato AL; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1262-8. PubMed ID: 23182395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
    World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive dosimetric parameters for gastrointestinal toxicity with hypofractioned radiotherapy in pancreatic adenocarcinoma.
    Liu X; Ren G; Li L; Xia T
    Onco Targets Ther; 2016; 9():2489-94. PubMed ID: 27217772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
    Hunter KU; Feng FY; Griffith KA; Francis IR; Lawrence TS; Desai S; Murphy JD; Zalupski MM; Ben-Josef E
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):921-6. PubMed ID: 22208966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
    Ben-Josef E; Shields AF; Vaishampayan U; Vaitkevicius V; El-Rayes BF; McDermott P; Burmeister J; Bossenberger T; Philip PA
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):454-9. PubMed ID: 15145162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.